![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Abbvie/J&J Combination Therapy Gets FDA Nod
Abbvie/J&J Combination Therapy Gets FDA Nod
![Grey Approved Stamp](https://www.fdanews.com/ext/resources/test/Drug-Images4/Grey_Approved_Stamp.gif?t=1576541258&width=430)
February 4, 2019
The FDA approved Abbvie and Johnson & Johnson’s Imbruvia (ibrutinib) and Gazyva (obinutuzumab) combination therapy.
The combination therapy is indicated for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Imbruvica was previously approved as a single agent or in combination with bendamustine and rituximab for CLL/SLL patients.
The FDA based the results on a Phase 3 trial that showed significantly improved progression-free survival compared to chlorambucil plus obinutuzumab. The agency also updated Imbruvica’s labeling to include additional long-term efficacy follow-up supporting its use as a single agent.
Upcoming Events
-
21Oct